In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
丙肝感染者中,重叠感染隐匿性HBV会影响干扰的疗效。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
丙肝感染者中,重叠感染隐匿性HBV会影响干扰的疗效。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰包括派罗欣治疗时存肝功能失代偿和死亡风险。
声明:以上例、词性分类均由互联网资源成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。